Functional Electrical Stimulation for Footdrop in Hemiparesis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00148343 |
|
Recruitment Status :
Completed
First Posted : September 7, 2005
Results First Posted : June 1, 2018
Last Update Posted : June 1, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
The objective of this research is to determine if electrical stimulation can improve the strength and coordination of the lower limb muscles, and the walking ability of stroke survivors.
The knowledge gained from this study may lead to enhancements in the quality of life of stroke survivors by improving their neurological recovery and mobility. The results may lead to substantial changes in the standard of care for the treatment of lower limb hemiparesis after stroke.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Stroke Hemiplegia | Device: Odstock Dropped-Foot Stimulator (ODFS) Other: Conventional Standard of Care Procedure: Traditional Physical Therapy Treatment | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 110 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Functional Electrical Stimulation for Footdrop in Hemiparesis |
| Study Start Date : | July 2005 |
| Actual Primary Completion Date : | August 2, 2010 |
| Actual Study Completion Date : | August 2, 2010 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: ODFS
Odstock Dropped-Foot Stimulator (ODFS)
|
Device: Odstock Dropped-Foot Stimulator (ODFS)
Device implementation & use for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators. Procedure: Traditional Physical Therapy Treatment Traditional physical therapy treatment for 12 weeks. |
|
Active Comparator: Standard of Care (inc. AFO)
Conventional Standard of Care (which may include a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) [Traditional Physical Therapy Treatment]
|
Other: Conventional Standard of Care
Conventional standard of care (which may include implementation & use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population. Procedure: Traditional Physical Therapy Treatment Traditional physical therapy treatment for 12 weeks. |
- Fugl-Meyer Motor Assessment (FMA) [ Time Frame: Weeks 0, 12, 24, 36 ]Lower limb motor impairment as measured by the lower limb portion of the Fugl-Meyer Assessment (FMA) which consists of 17 items, with a maximum possible score of 34 points, with lower scores indicating higher impairment. Each item was answered using a 3-point ordinal scale (0 = cannot perform, 1 = can partially perform, 2 = can fully perform).
- Steps Per Minute [ Time Frame: Weeks 0, 12, 24, 36 ]The number of steps taken by participants in one minute
- Modified Emory Functional Ambulation Profile(mEFAP) [ Time Frame: Weeks 0, 12, 24, 36 ]The mEFAP comprises 5 individually timed tasks performed over different environmental terrains. The subtasks include (1) a 5-meter walk on a hard floor; (2) a 5-meter walk on a carpeted surface; (3) rising from a chair, a 3-meter walk, and return to a seated position (the "timed up-and-go" test); (4) traversing a standardized obstacle course; and (5) ascending and descending 5 stairs. The mEFAP is performed with or without the use of an orthotic device or an AD. Manual assistance (MA) is provided as necessary. The subject can use rails when climbing the stairs. The 5 timed subscores are added to derive a total score in seconds.
- Stroke-Specific Quality of Life Scale (SS-QOL) [ Time Frame: Weeks 0, 12, 24, 36 ]
The Stroke Specific Quality Of Life scale (SS-QOL) is a patient-centered outcome measure intended to provide an assessment of health-related quality of life specific to patients with stroke. Patients must respond to each question of the SS-QOL with reference to the past week. It is a self-report scale containing 49 items in 12 domains: Mobility, Energy, Upper extremity function, Work/productivity, Mood, Self-care, Social roles, Family roles, Vision, Language, Thinking, Personality. There are 11 subscales.
Items are rated on a 5-point Likert scale with higher scores indicate better functioning. The overall SS-QOL summary score (summation of all items) is presented here. Scores range from 49-245.
- Gait Speed [ Time Frame: baseline, 12, 24 and 36 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Stroke survivors >90 days from most recent clinical hemorrhagic or nonhemorrhagic stroke
- Age: 18-80 years
- Unilateral hemiparesis
- Medically stable
- Sufficient endurance & motor ability to ambulate at least 30 feet continuously with minimal assistance [requiring contact guard to no more than 25% physical help] or less without the use of an AFO
- Berg Balance Scale score of 24 or greater without any assistive devices
- Ankle dorsiflexion strength of no greater than 4/5 on the Medical Research Council (MRC) scale while standing
- Demonstrate foot-drop during ambulation such that gait instability [need for supervision, physical assistance or assistive device (cane, walker) to maintain balance or prevent falls] or inefficient gait patterns [gait pattern manifesting "dragging" or "catching" of the affected toes during swing phase of gait, or use of compensatory strategies such as circumducting the affected limb, vaulting with the unaffected limb or hiking the affected hip to clear the toes] are exhibited
- Ankle dorsiflexion to at least neutral while standing in response to NMES of the common peroneal nerve without painful hypersensitivity to the NMES
- If using an AFO, willing to terminate its use and comply with study requirements
Exclusion Criteria:
- Require an AFO to maintain knee stability (prevention of knee flexion collapse) during stance phase of gait
- Edema of the affected lower limb which interferes with the safe and effective use of a peroneal nerve stimulator
- Skin breakdown of the affected lower limb which interferes with the safe and effective use of a peroneal nerve stimulator
- Absent sensation of the affected lower limb
- History of potentially fatal cardiac arrhythmias, such as ventricular tachycardia, supraventricular tachycardia, and rapid ventricular response atrial fibrillation with hemodynamic instability
- Demand pacemakers or any other implanted electronic systems
- Pregnant women
- Uncontrolled seizure disorder
- Parkinson's Disease
- Spinal cord injury
- Traumatic brain injury with evidence of motor weakness
- Multiple sclerosis
- Fixed ankle plantar flexor contracture
- Peroneal nerve injury at the fibular head as the cause of foot-drop
- Uncompensated hemineglect
- Severely impaired cognition and communication
- Painful hypersensitivity to NMES of the common peroneal nerve
- Inadequate social support (potential unlikeliness to comply with treatment & follow-up)
- History of Botulinum toxin (Botox) injection to either of the lower extremities within the 3 month period preceding study entry
- Knee hyperextension (genu recurvatum) that cannot be adequately corrected with peroneal nerve stimulation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00148343
| United States, Ohio | |
| MetroHealth Medical Center | |
| Cleveland, Ohio, United States, 44109 | |
| Principal Investigator: | John Chae, MD | MetroHealth Medical Center |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | John Chae, MD, Prof, Chair Physical Medicine and Rehabilitation, MetroHealth Medical Center |
| ClinicalTrials.gov Identifier: | NCT00148343 |
| Other Study ID Numbers: |
IRB04-00104 R01HD044816 ( U.S. NIH Grant/Contract ) |
| First Posted: | September 7, 2005 Key Record Dates |
| Results First Posted: | June 1, 2018 |
| Last Update Posted: | June 1, 2018 |
| Last Verified: | May 2018 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
|
hemiplegia hemiparesis stroke |
foot-drop electrical stimulation ankle-foot-orthosis |
|
Hemiplegia Paresis Nervous System Diseases Paralysis Neurologic Manifestations |

